American Heart Association Launches Initiative to Boost Aortic Stenosis Clinical Trial Participation
TL;DR
The American Heart Association's new initiative with Kardigan provides earlier access to innovative treatments, giving patients and providers an advantage in managing aortic stenosis.
The American Heart Association is expanding its Target: Aortic Stenosis program to connect patients with clinical trials through 40 hospitals and heart valve clinics.
This initiative helps people with aortic stenosis receive earlier diagnosis and treatment, creating healthier lives and advancing care for this serious heart condition.
Over 2,200 people with moderate aortic stenosis are already managed through this network, which now expands to include clinical trial opportunities.
Found this article helpful?
Share it with your network and spread the knowledge!
The American Heart Association has launched a new initiative to boost clinical trial participation and accelerate diagnosis of aortic stenosis, a common but frequently underdiagnosed heart valve condition that affects blood flow from the heart to the body. Aortic stenosis is characterized by the narrowing of the aortic valve opening, which when untreated can lead to severe complications including heart failure and death.
This new effort expands the Association's support for patients with moderate aortic stenosis by driving awareness of and access to clinical trials across its nationwide network of hospitals and heart valve clinics. The initiative leverages the established infrastructure of the Association's Target: Aortic Stenosis™ program, which already manages more than 2,200 people with moderate AS through its existing quality improvement network.
"Aortic stenosis is a serious condition, yet too often, people go undiagnosed until the disease progresses," said Sreekanth Vemulapalli, M.D., the Association's volunteer project clinical leader and volunteer member of the Target: Aortic Stenosis Scientific Advisory Group. "By identifying eligible participants for new clinical trials and supporting clinical research, this initiative will help shape the future of care for people affected by this disease."
The program will engage at least 40 hospitals and their affiliated heart valve clinics to connect more individuals with research opportunities, promoting emerging medical therapy alternatives and advancing guideline-based care. The initiative, supported by Kardigan, represents a significant step toward addressing the diagnostic delays that often characterize aortic stenosis management.
"We're proud to support this American Heart Association initiative to help connect patients with moderate aortic stenosis to promising research opportunities," said Jay Edelberg, M.D., Ph.D., co-founder and chief medical officer at Kardigan. "Improving access to clinical trials will not only advance innovation, but also help more people receive the diagnosis and treatment they need sooner."
As part of this comprehensive effort, the Association will provide professional education, quality improvement tools and site-level support to help clinicians better identify and refer individuals eligible for clinical trials. A health care provider climate survey will also explore barriers to trial enrollment and inform solutions that increase participation in structural heart disease research. The Target: Aortic Stenosis™ program receives additional support from Edwards Lifesciences, further strengthening the collaborative approach to addressing this cardiovascular challenge.
Curated from NewMediaWire
